Lacipil

Lacidipine, the active ingredient in Lacipil, is a calcium channel blocker presented as a tablet for oral use. It reduces high blood pressure by relaxing vascular smooth muscle, and is indicated for the treatment of hypertension in adult patients.

GNH USA supplies Lacipil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products that meet European Union regulatory standards. The company follows stringent Good Distribution Practice and provides reliable logistics for global markets and supports post‑marketing surveillance.

Lacidipine is used to manage hypertension, a condition characterized by chronically elevated arterial pressure.

Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular complications.

Lacidipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness - Nausea

Serious or Rare Side Effects: - Severe hypotension - Angioedema - Hepatic dysfunction - Myocardial infarction

When prescribing lacidipine, clinicians should consider several safety precautions to minimize risk.

Blood pressure monitoring: regularly assess to avoid excessive hypotension. Hepatic impairment: use with caution and consider dose adjustment. Elderly patients: start at low dose and monitor for dizziness. Concomitant antihypertensives: evaluate for additive blood pressure lowering effects. Hypersensitivity: discontinue if allergic reaction occurs. Store at room temperature: keep in original packaging, protect from moisture and light.

Lacidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacidipine plasma levels, risking toxicity. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness by lowering drug concentrations. - Other potent vasodilators (e.g., nitroglycerin): can cause additive hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance blood pressure lowering effect, requiring dose adjustments. - Diuretics: combined use may increase risk of electrolyte imbalance and hypotension. - Grapefruit juice: can modestly raise lacidipine levels, advise patients to limit consumption.